Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Lymphatic Metastasis 1

Interventions

pembrolizumab 31Carboplatin 24Specimen Handling 19Magnetic Resonance Spectroscopy 17Cyclophosphamide 17Nivolumab 14Dexamethasone 14Bevacizumab 13fludarabine 12atezolizumab 11Temozolomide 11Gemcitabine 11Biopsy 11Paclitaxel 10venetoclax 9Pemetrexed 9Ipilimumab 9Cisplatin 8Rituximab 7Prednisone 7Oxaliplatin 7Lenalidomide 7Fluorouracil 7Docetaxel 7Capecitabine 7olaparib 6Vincristine 6Leucovorin 6patritumab deruxtecan 5lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × peposertib × 30 days × Clear all
NCT04071236 2026-06-05

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

National Cancer Institute (NCI)

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Lymphatic Metastasis, Prostatic Neoplasms

NCT04172532 2026-06-02

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
92 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡